- Organizations: Stuart Therapeutics
Pipeline
Stuart Therapeutics submits IND amendment for corneal wound healing
Planned proof-of-concept study is the first expansion beyond DED indication for ST-100 (vezocolmitide), with a phase 2 trial to follow in H2 2027.Business
Leadership watch: Samsara, Claris Bio, Staar Surgical, Wills Eye, and more
Leadership changes are underway in the eyecare space—and we’ve got the latest.Pipeline
Stuart Therapeutics reports initial phase 3 DED eye drop data
Results on ST-100 (vezocolmitide), a collagen mimetic peptide, support its role as a fast-acting resolution for dry eye signs and symptoms.Pipeline
Stuart Therapeutics initiates phase 3 DED trial for vezocolmitide
Topical formulation aims to improve tear production, symptom relief, and reduce ocular surface damage.Pipeline